Biodesix lowers full-year sales outlook as quarter misses internal growth target

Biodesix (Nasdaq: BDSX) has reduced its revenue forecast for 2026 to between $101m and $103m after its third quarter came in below what management had planned. The company reported the results on 5 November.

Sales for the three months reached $24.0m, a 10% rise on the same period last year. Within that, the Diagnostic Testing arm grew 16%, helped by a 24% increase in the number of tests run. The company's summary does not explain why revenue grew more slowly than volume, so the effect of pricing, payer mix or other factors cannot be determined from the material available.

Management gave three reasons for the miss: a smaller sales representative team, a stronger seasonal pattern than it had anticipated, and delays to projects in its Development Services business, which serves biopharma customers. The material reviewed does not quantify how much each factor contributed.

Biodesix also pointed to a lung nodule programme framework from CHEST that backs the use of biomarker testing, citing its Nodify Lung test as an example of such tools. It further noted new programmes in digital diagnostics and minimal residual disease (MRD) testing, but no details on either were available, including scope, timing or regulatory route.